Regeneron Pharmaceuticals Inc. (REGN) | stock, history and financial record short review for 2022

Regeneron Pharmaceuticals Inc. (REGN) | stock, history and financial record short review for 2022, Bio Data Technology: Bioinformatics and Biotechnology directory

Regeneron Pharmaceuticals is one of pioneering biotechnology companies with highest value share in Nasdaq that in this report we will have a short complete review and its economical function.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York, about 25 miles north of Midtown Manhattan. The company was founded in 1988.

Biopharmaceutical company Regeneron develops and markets drug treatments for patients with eye disease, cancer, cardiovascular diseases, allergic and inflammatory issues, and infectious diseases. Through its Regeneron Genetics Center, the company aims to conduct one of the largest gene sequencing operations worldwide.

Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.

Regeneron Pharmaceuticals Inc financial record for 2021

Revenue (TTM): $7.9 billion

Net Income (TTM): $2.1 billion

Market Cap: $49.5 billion

1-Year Trailing Total Return: 14.7%

Exchange: Nasdaq.

What does Regeneron specialize in?

Regeneron is a biopharmaceutical company specializing in antibody treatments for rare and serious diseases.

Is Regeneron solution effective against Covid?

Regeneron’s COVID antibody loses effectiveness against omicron, so it’s working on a new version. After admitting that its COVID-19 antibody REGEN-COV loses its effectiveness against the omicron variant, Regeneron revealed that it is working on a new treatment to defend against the mutated strain.

How many medicines does Regeneron have?

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories.

Why is Regeneron going down?

The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. REGN stock plunged 6% in Friday (Oct 1) trade after Merck announced positive data for its Covid-19 antiviral oral pill.

X
%d bloggers like this: